Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
RESEARCH LETTER

Association of Kidney Function With 30-Day Mortality Following SARS-CoV-2 Infection in Nursing Home Residents: A Retrospective Cohort Study

To the Editor:

Nursing home residents are a high-risk group for adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection owing to advanced age, multimorbidity, and frailty. Chronic kidney disease (CKD) is a significant independent predictor of mortality in nursing home residents with SARS-CoV-2 and in the general population. However, the relationship between CKD stage and SARS-CoV-2 mortality has not been explored among nursing home residents. We described the association between kidney function and all-cause 30-day mortality following SARS-CoV-2 diagnosis among nursing home residents. We hypothesized that mortality would increase progressively with worsening kidney function.

This retrospective cohort study linked nursing home electronic health record data to Minimum Data Set (MDS) assessments to identify nursing home residents with an incident SARS-CoV-2 infection between March 1, 2020 and December 31, 2020 (Table S1, Figure S1). The main exposure of interest was kidney function, categorized according to the KDIGO definition (ie, G1-G5) using each resident’s median baseline estimated glomerular filtration rate (eGFR) (Item S1). The outcome was all-cause mortality within 30 days of the resident’s SARS-CoV-2 diagnosis. We included a number of baseline person-level characteristics to better isolate the independent association between kidney function and all-cause mortality following SARS-CoV-2 infection. These included age, sex, comorbidities (Table S2), medication use within 7 days prior to SARS-CoV-2 diagnosis (Table S3), and calendar month of diagnosis.

To model the association between kidney function and death following SARS-CoV-2 infection, we used multivariable logistic regression models and postestimation commands to calculate the adjusted probability of mortality and adjusted risk ratios (Item S2). We also explored whether the association differed by other known risk factors for SARS-CoV-2 mortality (diabetes status and glycemic control, age, and degree of functional and cognitive impairment; Item S2) and tested alternative modeling specifications (Item S2) and approaches to characterizing baseline kidney function (Item S1). Brown University’s Institutional Review Board approved the study and waived the requirement for informed consent.

During calendar year 2020, 6,798 residents had a confirmed new SARS-CoV-2 infection and met the cohort inclusion requirements (Figure S1). Overall, 75% of the study cohort were non-Hispanic White and 61% were female; residents in the G5 group had lower rates of cognitive and functional impairment but higher rates of most comorbidities (Table S4). Fifteen percent died within 30 days of SARS-CoV-2 diagnosis. In adjusted analyses, mortality risk was progressively greater with worse kidney function: 10.1% (95% CI, 8.3%-11.9%) of those in the G1 group died within 30 days, while 23.2% (95% CI, 18.6%-27.7%) of those in the G5 group died. Compared with group G1, the risk of death ranged from 1.4 (95% CI, 1.2-1.7) times higher for group G2 to 2.3 (95% CI, 1.8-3.0) times higher for group G5 (Table 1).

Adjusted mortality was generally greater with worse kidney function among subgroups with known risk factors for SARS-CoV-2 mortality (Figure 1). Stability analyses that used alternative model specifications (Tables S5-S7) or methods of categorizing kidney function (Tables S8 and S9) were consistent with the main analysis.

Studies have shown higher SARS-CoV-2 mortality among hospitalized older adults with CKD, and among nursing home residents with kidney failure or decreased kidney function documented in the MDS. Our study corroborates and expands upon these findings by using creatinine-based determination of kidney function, allowing a more granular assessment of how level of kidney function is associated with mortality.

Our study has a number of limitations. The outcome was all-cause mortality rather than cause-specific SARS-CoV-2 mortality, which may be of separate interest. Our method for classifying kidney function may have misclassified some individuals. We also may have incomplete information about deaths among residents who were discharged from and not readmitted to the nursing home. However, hospitalization rates were higher for residents with worse kidney function, who already had higher mortality, suggesting that our estimates would, if anything, underestimate deaths for these residents.

While more severe cognitive and functional impairments are significant predictors of SARS-CoV-2 mortality among nursing home residents, even adjusting for and stratifying by these factors we find a large association between decreased eGFR and mortality that is greater with worsening kidney function. This suggests that kidney function, while related to age, multimorbidity, and frailty, is independently associated with death following SARS-CoV-2. Despite widespread availability of vaccines to nursing home residents, SARS-CoV-2 remains a threat. Understanding which individuals are particularly vulnerable will remain important for risk mitigation strategies.

Rebecca Thorsness, PhD, Nathan H. Raines, MD, MPH, Elizabeth M. White, PhD, APRN, Christopher M. Santostefano, BSN, RN, Samir M. Parikh, MD, Melissa R. Riezer, PharmD, Richard A. Feifer, MD, MPH, Vincent Mor, PhD, and Andrew R. Zullo, PharmD, PhD

Supplementary Material

Supplementary File (PDF)
### Table 1. Thirty-Day All-Cause Mortality Among Nursing Home Residents Who Tested Positive for SARS-CoV-2, by GFR Category

|        | G1 (eGFR >90) | G2 (eGFR 60-89) | G3a (eGFR 45-59) | G3b (eGFR 30-44) | G4 (eGFR 15-29) | G5 (eGFR <15 or Dialysis) |
|--------|---------------|----------------|-----------------|-----------------|----------------|--------------------------|
| **Unadjusted** | | | | | | |
| Probability | 7.31% (5.90%-8.72%) | 15.56% (13.79%-17.34%) | 17.92% (15.57%-20.28%) | 18.91% (15.82%-20.00%) | 24.70% (20.36%-29.05%) | 18.32% (14.00%-22.64%) |
| Risk ratio | 1.00 (reference) | 2.13 (1.77-2.55) | 2.45 (2.00-3.01) | 2.59 (2.08-3.21) | 3.38 (2.60-4.39) | 2.51 (1.85-3.39) |
| **Adjusted model** | | | | | | |
| Probability | 10.09% (8.33%-11.85%) | 14.46% (12.98%-15.94%) | 16.35% (14.31%-18.39%) | 17.42% (14.78%-20.06%) | 21.76% (17.75%-25.78%) | 23.16% (18.62%-27.70%) |
| Risk ratio | 1.00 (reference) | 1.43 (1.19-1.72) | 1.62 (1.34-1.96) | 1.73 (1.41-2.12) | 2.16 (1.69-2.75) | 2.30 (1.77-2.97) |

Median baseline serum creatinine was used to calculate estimated glomerular filtration rate (eGFR, in mL/min/1.73 m²), which was categorized in G (glomerular filtration rate) categories per the KDIGO 2012 guideline\(^{12}\) (dialysis determined by a Minimum Data Set indicator for dialysis treatment). Adjusted model adjusts for resident characteristics including age, sex, long stay status, degree of cognitive and functional impairment, comorbidities, medication use during the 7 days prior to SARS-CoV-2 infection, and calendar month of SARS-CoV-2 diagnosis. Predicted probabilities and risk ratios were calculated following logistic regression, with 95% CI in parentheses. Models clustered robust standard errors at the nursing home facility level.

### Article Information

**Authors’ Affiliations:** Department of Health Services, Policy, and Practice (RT, EMW, MRR, VM, ARZ) and Center for Gerontology and Healthcare Research (EMW, CMS, MRR, VM, ARZ), Brown University School of Public Health, Providence, Rhode Island; Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts (NHR, SMP); Genesis Healthcare, Kennett Square, Pennsylvania (RAF); and Center of Innovation in Long Term Services and Supports, Providence Veterans Affairs Medical Center, Providence, Rhode Island (VM, ARZ).

**Address for Correspondence:** Rebecca Thorsness, PhD, 121 S Main St, Floor 7, Providence, RI 02903. Email: rebecca_thorsness@brown.edu

**Authors’ Contributions:** Research idea and study design: all authors; data acquisition: VM, RAF; statistical analysis: RT, CMS; interpretation: all authors; supervision/mentorship: ARZ, SMP, VM. Each author contributed important intellectual content during manuscript drafting or revision and agrees to be personally accountable for the individual’s own contributions and to ensure that questions pertaining to the accuracy or integrity of any portion of the work, even one in which the author was not directly involved, are appropriately investigated and resolved, including with documentation in the literature if appropriate.

**Support:** This research was supported by the National Institute on Aging (NIA) (3P01AG027296-11S1; Principal Investigator: VM). NHR is supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant T32 DK007199 (Pollak) and the Doris Duke Physician Scientist Fellowship grant 63408. SMP involved, are appropriately investigated and resolved, including with documentation in the literature if appropriate.

**Figure 1.** Adjusted 30-day all-cause mortality following SARS-CoV-2 infection by glomerular filtration rate (GFR) category and SARS-CoV-2 risk factors. In nearly all subgroups, mortality increases with advancing GFR category, suggesting kidney function is associated with SARS-CoV-2 mortality independent of these risk factors. Models adjust for all resident characteristics other than the risk factor under investigation, including age, sex, long stay status, degree of cognitive and functional impairment, comorbidities, medication use during the 7 days prior to SARS-CoV-2 infection, and calendar month of SARS-CoV-2 diagnosis. Predicted probabilities were calculated following logistic regression. Models clustered robust standard errors at the nursing home facility level. Owing to collinearity, adjusted probability of mortality was not estimable for residents in the G5 group with hemoglobin A1c ≥8.5%.
is supported by grants R35HL139424, R01DK095072, and R01AG027002 from the National Heart Lung Blood Institute, NIDDK, and NIA. ARZ is supported by NIA grants R01AG045441, RF1AG061221, R01AG065722, and R21AG061632. Funders played no role in study design; collection, analysis, and interpretation of data; writing the report; or the decision to submit the report for publication.

Financial Disclosure: SMP is a consultant for Janssen and Mission Therapeutics; member of scientific advisory boards for Cyto kinetics and Aerea; and recipient of royalties from UpToDate and honoraria from the American Society of Nephrology. ARZ is supported by grant funding paid directly to Brown University by Sanofi Pasteur for collaborative research on infections and vaccinations in nursing home residents as well as respiratory syncytial virus in infants. VM serves as Chair of the Scientific Advisory Committee at NaviHealth, Inc, was former Chair of the Independent Quality Committee at HCR ManorCare, and is the former Director of PointRight Inc, where he holds less than 1% equity; and received personal fees from NaviHealth outside the submitted work. The remaining authors declare that they have no relevant financial interests.

Acknowledgements: We thank Jeff Hinis, Yoojin Lee, and Cyrus Kosar from Brown University and the Genesis HealthCare IT leadership team for their ongoing technical support and guidance on this project.

Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US Government.

Peer Review: Received June 8, 2021. Evaluated by 2 external peer reviewers, with direct editorial input from a Statistics/Methods Editor, an Associate Editor, and the Editor-in-Chief. Accepted in revised form September 12, 2021.

Publication Information: © 2021 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. Published online October 14, 2021 with doi 10.1053/j.ajkd.2021.09.009

RESEARCH LETTER
Seroreponse to SARS-CoV-2 Vaccines Among Maintenance Dialysis Patients
To the Editor:

As of October 2021, 3 SARS-CoV-2 vaccines are available in the United States, and all appear highly effective in the general population. Studies suggest high seroreponse to messenger RNA vaccines among maintenance dialysis patients, albeit lower than that in the general population. Data regarding adenoviral vector vaccines and predictors of vaccine nonresponse are limited by small sample sizes. Accordingly, we retrospectively analyzed seroreponse to SARS-CoV-2 vaccines among maintenance dialysis patients, updating an earlier report.

DCI is a national not-for-profit provider caring for more than 15,000 patients at 260 outpatient dialysis clinics across 29 states. As of January 2021, DCI physicians had the option of activating a SARS-CoV-2 vaccine protocol, in which anti–spike immunoglobulin G antibodies (SAb-IgG) were measured monthly with routine lab work (details in Item S1). We obtained demographic and clinical data, vaccination dates, and SAb-IgG titers from the DCI electronic health record. We excluded patients with previously diagnosed COVID-19 or positive SAb-IgG titer before or within 10 days after first vaccine dose.

In primary analyses, seroreponse was defined by at least one ≥1 SAb-IgG titer ≥1 U/L at 14–74 days after completion of a vaccine series. Because samples for antibody titer were drawn alongside monthly labs, most patients have 2 assessments in this 60-day period. Associations of demographic and clinical factors with vaccine seroreponse were analyzed using multivariable log Poisson regression with robust variances. Secondary analyses used alternate definitions of vaccine seroreponse: (1) ≥1 SAb-IgG titer ≥2 U/L at 14–74 days after vaccine series completion, and (2) SAb-IgG titer ≥1 U/L on the first assessment at least 14 days after vaccine series completion. This study was reviewed and approved by the WCG IRB (Work Order 1-1456342-1) with exemption for informed consent. Statistical analyses were performed using SAS v9.4.

Between January 1 and June 30, 2021, 1,528 patients (437 BNT162b2/Pfizer, 766 mRNA-1273/Moderna, and 325 Ad26.COV2.S/Janssen recipients) across 130 dialysis facilities had SAb-IgG titers measured after SARS-CoV-2 vaccination (Fig S1). Baseline characteristics were similar to those of the broader DCI vaccinated patient population. Between 14 and 74 days after vaccine series completion,

References
1. Grabowski DC, Mor V. Nursing home care in crisis in the wake of COVID-19. JAMA. 2020;324(1):23.
2. Panagiotou OA, Kosar CM, White EM, et al. Risk factors associated with all-cause 30-day mortality in nursing home residents with COVID-19. JAMA Intern Med. 2021;181(4):439-448.
3. Mehta HB, Li S, Goodwin JS. Risk factors associated with SARS-CoV-2 infections, hospitalization, and mortality among US nursing home residents. JAMA Netw Open. 2021;4(3):e216915.
4. Tarazi WW, Finegold K, Sheingold SH, Wong Samson L, Zuckerman R, Bosworth A. COVID-19-related deaths and excess deaths among Medicare fee-for-service beneficiaries. Health Affairs. 2021;40(6):879-885.
5. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-436.
6. Akhurin O, Meza K, Biswas S, et al. COVID-19 in patients with CKD in New York City. Kidney360. 2021;2(1):63-70.
7. Pakhchanian H, Raiser R, Mukherjee A, Khan A, Singh S, Chatterjee A. Outcomes of COVID-19 in CKD patients: a multicenter electronic medical record cohort study. CJASN. 2021;16(5):785-786.
8. Oetjens MT, Luo JZ, Chang A, et al. Electronic health record analysis identifies kidney disease as the leading risk factor for hospitalization in confirmed COVID-19 patients. PLos One. 2020;15(11):e0242182.
9. Flythe JE, Assimon MM, Tugman MJ, et al. Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to intensive care units in the United States. Am J Kidney Dis. 2021;77(2):190-203.e1.
10. Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014;85(1):49-61.